{"id":831635,"date":"2025-03-31T08:38:20","date_gmt":"2025-03-31T12:38:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/"},"modified":"2025-03-31T08:38:20","modified_gmt":"2025-03-31T12:38:20","slug":"lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/","title":{"rendered":"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100"},"content":{"rendered":"
\n

\n
\n Pre-Clinical Study in Collaboration with Netherlands Cancer Institute<\/em>
\n <\/strong>
\n
\n
\n is in addition to LIXTE\u2019s Ongoing Clinical Trials for Ovarian and Colorectal Cancers<\/em>
\n <\/strong>\n <\/p>\n

\n PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) — <\/strong>
\n LIXTE Biotechnology Holdings, Inc<\/a>. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT<\/a> and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether \u201cinitiated\u201d cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE\u2019s proprietary compound LB-100.<\/p>\n

\u201cIn addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new opportunity in cancer prevention,\u201d said Bas van der Baan, LIXTE\u2019s Chief Executive Officer. \u201cThus far in our Phase 1 clinical trials, LB-100 has shown patient tolerance, with little toxicity, making it a promising candidate as a broad and effective cancer prevention modality.\u201d<\/p>\n

Increasing evidence indicates that as individuals age, certain mutations accumulate that are found in cancer cells. While these \u201cinitiated\u201d cells behave essentially normally, they can propagate to form reservoirs of pre-malignant cells from which malignant cells may eventually emerge. Recent data from LIXTE\u2019s ongoing clinical collaboration with NKI shows that LB-100 activates oncogenic signaling and that this is detrimental to cancer cells.<\/p>\n

The new study in animal models will investigate whether \u201cinitiated\u201d cells, harboring a mutant RAS oncogene, can be eliminated with LB-100. If successful, LB-100 could have a significant role in the elimination of initiated cells in aged individuals and could reduce the risk of developing a wide range of cancers as a person ages.<\/p>\n

The study will be led by Ren\u00e9 Bernards, Ph.D., a global leader in the field of molecular carcinogenesis and Senior Staff Scientist at NKI, one of the world\u2019s leading comprehensive cancer centers. Dr. Bernards also is a member of LIXTE\u2019s Board of Directors.<\/p>\n

\n About LIXTE Biotechnology Holdings, Inc. <\/strong>\n <\/p>\n

\n LIXTE Biotechnology Holdings, Inc<\/a>. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com<\/a>), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.<\/p>\n

LIXTE\u2019s lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology \u2013\u00a0activation lethality\u00a0\u2013 that is advancing a new treatment paradigm. LIXTE’s new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for colon, small cell lung and sarcoma cancers. Additional information about LIXTE can be found at\u00a0www.lixte.com<\/a>.<\/p>\n

\n Forward-Looking Statement Disclaimer\u00a0<\/strong>\n <\/p>\n

This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company’s intellectual property worldwide, and the Company\u2019s ability to obtain and maintain compliance with Nasdaq\u2019s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as “intend,” anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology.<\/p>\n

The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.<\/p>\n

Readers are urged to read the risk factors set forth in the Company\u2019s filings with the United States Securities and Exchange Commission at https:\/\/www.sec.gov<\/a>. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n

\n For more information about LIXTE, contact: <\/strong>
\n
\n info@lixte.com<\/u>
\n <\/a>
\n
General Phone: (631) 830-7092; Investor Phone: (888) 289-5533<\/p>\n

or<\/p>\n

PondelWilkinson Inc. Investor Relations pwinvestor@pondel.com<\/u><\/a>
Roger Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE\u2019s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether \u201cinitiated\u201d cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE\u2019s proprietary compound LB-100. \u201cIn addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new opportunity in cancer prevention,\u201d said Bas van der Baan, LIXTE\u2019s Chief Executive Officer. \u201cThus far in our Phase 1 … <\/p>\n

Continue reading “LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-831635","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nLIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE\u2019s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether \u201cinitiated\u201d cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE\u2019s proprietary compound LB-100. \u201cIn addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new opportunity in cancer prevention,\u201d said Bas van der Baan, LIXTE\u2019s Chief Executive Officer. \u201cThus far in our Phase 1 … Continue reading "LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-31T12:38:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100\",\"datePublished\":\"2025-03-31T12:38:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/\"},\"wordCount\":810,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/\",\"name\":\"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==\",\"datePublished\":\"2025-03-31T12:38:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/","og_locale":"en_US","og_type":"article","og_title":"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - Market Newsdesk","og_description":"Pre-Clinical Study in Collaboration with Netherlands Cancer Institute is in addition to LIXTE\u2019s Ongoing Clinical Trials for Ovarian and Colorectal Cancers PASADENA, Calif., March 31, 2025 (GLOBE NEWSWIRE) — LIXTE Biotechnology Holdings, Inc. (\u201cLIXTE\u201d or the \u201cCompany\u201d) (Nasdaq: LIXT and LIXTW), a clinical stage pharmaceutical company, today announced it will conduct a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether \u201cinitiated\u201d cells that carry mutations found in cancer cells can be eliminated by treatment with LIXTE\u2019s proprietary compound LB-100. \u201cIn addition to our ongoing clinical trials in ovarian and colorectal cancer, this study represents a new opportunity in cancer prevention,\u201d said Bas van der Baan, LIXTE\u2019s Chief Executive Officer. \u201cThus far in our Phase 1 … Continue reading \"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-31T12:38:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100","datePublished":"2025-03-31T12:38:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/"},"wordCount":810,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/","name":"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==","datePublished":"2025-03-31T12:38:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxMzI3NCM2ODQwOTY0IzUwMDAyNTY5NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lixte-launches-new-study-to-determine-if-certain-pre-cancerous-cells-found-in-an-aging-population-can-be-eliminated-by-lb-100\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831635","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=831635"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/831635\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=831635"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=831635"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=831635"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}